Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report

Activating mutations in the epidermal growth factor receptor (EGFR) gene are the first validated biomarker to predict significant progression-free survival (PFS) benefit with treatment with EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) (1-5)